#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cushing's syndrome Follicle centre lymphoma follicular grade I, II – III Chronic myeloid leukaemia B-cell lymphoma Peripheral primitive neuroectodermal tumour of soft tissue Infective uveitis Ehlers-Danlos syndrome Anal fistula Mastocytosis Primary amyloidosis Alveolar proteinosis Gaucher's disease type III Mantle cell lymphoma stage III Breast cancer Hydrocephalus More trials…

    Learn about Rare Diseases

    Crigler-Najjar syndrome Brain stem glioma Pemphigoid – Life with Disease Malignant fibrous histiocytoma – Basic Information Shprintzen-Goldberg syndrome – Basic Information Leiomyosarcoma recurrent – Life with Disease Haemophilia A without inhibitors Mantle cell lymphoma stage IV – Basic Information Anaplastic thyroid cancer – Basic Information Hereditary neuropathic amyloidosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Linvoseltamab PROMESTRIENE Elexacaftor Tenofovir Disoproxil Trametinib Dimethyl Sulfoxide Levosimendan ICOTROKINRA Clonazepam Tiragolumab Xenon (129Xe) Sodium Sulfate Anhydrous Ambrisentan Elezanumab GSKVX000000030918 Retinol Acetate OXYBUTYNIN HYDROCHLORIDE Gs-1427 Amlodipine Besilate Rosuvastatin Calcium SGT-003 More therapies…

    Learn about Your Condition

    Rectal adenocarcinoma Muscle hypertrophy Gestational diabetes Vomiting Cardiac failure Emphysema Cystic fibrosis Infant sedation Primary hypercholesterolaemia Inflammation Oesophageal food impaction Meningioma malignant Anaplastic thyroid cancer Transplant rejection Cortisol abnormal More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Transitional cell carcinoma

  • Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    Czechia Denmark France Germany Greece Italy +5

  • Study on the Safety and Effectiveness of Erdafitinib Alone or with Cetrelimab and Chemotherapy for Patients with Metastatic or Advanced Urothelial Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Carboplatin
    • Cetrelimab
    Spain

  • Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Italy Poland Spain Sweden

  • Study Comparing Erdafitinib with Vinflunine, Docetaxel, or Pembrolizumab for Patients with Advanced Urothelial Cancer and FGFR Gene Changes

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Vinflunine
    • Docetaxel
    Belgium France Spain

  • Study of TYRA-300 for Patients with Advanced Bladder Cancer and Other Solid Tumors with FGFR3 Gene Changes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Transitional cell carcinoma
    • Neoplasm
    Investigated Drugs:
    • Tyra-300-B01
    France Italy Spain

  • Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Disitamab Vedotin
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Greece Hungary +7
Previous Page
1 … 4 5 6 7 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!